Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute myeloid leukemia (AML) for residual disease before receiving a bone marrow ...

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research (NIHR) ...

Qlucore, listed on Nasdaq First North, announces the launch of a new Qlucore Insights test (Research Use Only) specifically developed for Acute Myeloid Leukemia (AML). The software-based test delivers ...

A 51-year-old woman from Wimbledon, England, says testing positive for leukemia actually saved her life—thanks to a new bone marrow test being studied in a clinical trial. Jan Leahy, a business ...

MRD status before allo-HSCT is a strong prognostic factor for OS, DFS, and CIR in AML and MDS patients. MRD-negative patients showed significantly better OS and DFS compared to MRD-positive patients, ...